Literature DB >> 8125475

Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

E Voskoboeva1, D Isbrandt, K von Figura, X Krasnopolskaya, C Peters.   

Abstract

Mucopolysaccharidosis type VI (MPSVI, Maroteaux-Lamy syndrome) is a lysosomal storage disease for which multiple clinical phenotypes have been described. A deficiency of the enzyme arylsulfatase B (ASB, N-acetylgalactosamine-4-sulfatase) is the cause of this autosomal recessively inherited disorder. The genotypes of two patients with an intermediate form of MPSVI have been determined by polymerase chain reaction (PCR) amplification of the entire open reading frame of the ASB gene and subsequent direct sequencing of both strands of the PCR fragments by an automated nonradioactive approach. In patient A, a C to T transition in allele I resulting in an exchange of the Arg codon 160 for a premature stop codon (R160*, exon 2), and a G to A transition in allele II leading to a Gln to Arg160 substitution (R160Q, exon 2) were detected. Patient B exhibited a 7-bp deletion in exon 1 of allele I resulting in a frame shift and a premature stop codon 33 triplets 3' of the site of deletion (delta G237-C243), and a C to T transition in allele II giving rise to a Trp to Arg152 substitution (R152W, exon 2). None of these four mutant alleles was present among 60 alleles of the ASB gene in unrelated controls, indicating that the former are not polymorphisms. These results emphasize the broad molecular heterogeneity of Maroteaux-Lamy syndrome and contribute to the establishment of a genotype/phenotype correlation in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8125475     DOI: 10.1007/bf00212019

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  11 in total

1.  A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses.

Authors:  C A Pennock
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

2.  Structure of the human arylsulfatase B gene.

Authors:  S Modaressi; K Rupp; K von Figura; C Peters
Journal:  Biol Chem Hoppe Seyler       Date:  1993-05

3.  Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndrome.

Authors:  R Matalon; B Arbogast; A Dorfman
Journal:  Biochem Biophys Res Commun       Date:  1974-12-23       Impact factor: 3.575

4.  Mucopolysaccharidosis type VI: identification of three mutations in the arylsulfatase B gene of patients with the severe and mild phenotypes provides molecular evidence for genetic heterogeneity.

Authors:  W D Jin; C E Jackson; R J Desnick; E H Schuchman
Journal:  Am J Hum Genet       Date:  1992-04       Impact factor: 11.025

5.  Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.

Authors:  G Wicker; V Prill; D Brooks; G Gibson; J Hopwood; K von Figura; C Peters
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

6.  An N-acetylgalactosamine-4-sulfatase mutation (delta G238) results in a severe Maroteaux-Lamy phenotype.

Authors:  T Litjens; C P Morris; E F Robertson; C Peters; K von Figura; J J Hopwood
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

7.  Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B.

Authors:  C Peters; B Schmidt; W Rommerskirch; K Rupp; M Zühlsdorf; M Vingron; H E Meyer; R Pohlmann; K von Figura
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

8.  Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes.

Authors:  D Isbrandt; G Arlt; D A Brooks; J J Hopwood; K von Figura; C Peters
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

9.  Maroteaux-Lamy disease (mucopolysaccharidosis VI), subtype A: deficiency of a N-acetylgalactosamine-4-sulfatase.

Authors:  J F O'Brien; M Cantz; J Spranger
Journal:  Biochem Biophys Res Commun       Date:  1974-10-08       Impact factor: 3.575

10.  Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and C.

Authors:  E H Schuchman; C E Jackson; R J Desnick
Journal:  Genomics       Date:  1990-01       Impact factor: 5.736

View more
  11 in total

1.  Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients.

Authors:  T Litjens; D A Brooks; C Peters; G J Gibson; J J Hopwood
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

2.  A case of mucopolysaccharidosis type VI in a polish family. Importance of genetic testing and genotype-phenotype relationship in the diagnosis of mucopolysaccharidosis.

Authors:  Barbara Zapała; Olaf Chmura; Urszula Ciałowicz; Bogdan Solnica; Magdalena Krajewska-Włodarczyk; Zbigniew Żuber
Journal:  Mol Genet Metab Rep       Date:  2020-10-28

3.  Molecular Analysis of Turkish Maroteaux-Lamy Patients and Identification of One Novel Mutation in the Arylsulfatase B (ARSB) Gene.

Authors:  Alessandra Zanetti; Neslihan Onenli-Mungan; Nursel Elcioglu; Mehmet Nuri Ozbek; Deniz Kör; Elisabetta Lenzini; Maurizio Scarpa; Rosella Tomanin
Journal:  JIMD Rep       Date:  2013-11-16

4.  Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.

Authors:  Rita Ferla; Pamela Claudiani; Marco Savarese; Karen Kozarsky; Rossella Parini; Maurizio Scarpa; Maria Alice Donati; Giovanni Sorge; John J Hopwood; Giancarlo Parenti; Simona Fecarotta; Vincenzo Nigro; Hatice Serap Sivri; Ans Van Der Ploeg; Generoso Andria; Nicola Brunetti-Pierri; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2015-03       Impact factor: 5.695

Review 5.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

6.  Case Report: Reinterpretation and Reclassification of ARSB:p.Arg159Cys Variant Identified in an Emirati Patient With Hearing Loss Caused by a Pathogenic Variant in the CDH23 Gene.

Authors:  Nahid Al Dhahouri; Amanat Ali; Jozef Hertecant; Fatma Al-Jasmi
Journal:  Front Pediatr       Date:  2022-02-03       Impact factor: 3.418

7.  Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.

Authors:  Marion M Brands; Marianne Hoogeveen-Westerveld; Marian A Kroos; Willemieke Nobel; George J Ruijter; Lale Özkan; Iris Plug; Daniel Grinberg; Lluïsa Vilageliu; Dicky J Halley; Ans T van der Ploeg; Arnold J Reuser
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

Review 8.  Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literature.

Authors:  Agnieszka Jurecka; Ekaterina Zakharova; Vera Malinova; Elena Voskoboeva; Anna Tylki-Szymańska
Journal:  Clin Rheumatol       Date:  2013-11-13       Impact factor: 2.980

9.  Mutations in ARSB in MPS VI patients in India.

Authors:  Juby Mathew; Sujatha M Jagadeesh; Meenakshi Bhat; S Udhaya Kumar; Saravanamuthu Thiyagarajan; Sudha Srinivasan
Journal:  Mol Genet Metab Rep       Date:  2015-07-17

10.  Novel mutations of the arylsulphatase B (ARSB) gene in Indian patients with mucopolysaccharidosis type VI.

Authors:  Anusha Uttarilli; Prajnya Ranganath; S Jamal Md Nurul Jain; C Krishna Prasad; Anupam Sinha; Ishwar C Verma; Shubha R Phadke; Ratna D Puri; Sumita Danda; Mamta N Muranjan; Ganesh Jevalikar; H A Nagarajaram; Ashwin B Dalal
Journal:  Indian J Med Res       Date:  2015-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.